Heterogeneous Corneal Toxicity Among Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Focus on Osimertinib
Cornea Open · 2026-09 · 5 (3)
DOI: 10.1097/coa.0000000000000087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cornea Open, 2026-09. Verfasst von Claude Kaufmann und 2 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
To report a case of unilateral new-onset keratitis after years of cancer therapy with osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and to review the patterns of EGFR TKI–induced corneal toxicity.
Methods
A 56-year-old female patient presented with unilateral visual deterioration, ocular pain, and redness. Examination revealed ciliary injection, corneal erosions, a perilimbal infiltrate, and stromal edema. The patient had been undergoing treatment with the EGFR TKI osimertinib (Tagrisso) for 3 and a half years because of non-small cell lung cancer. An infectious cause was excluded through repeated scrapings and biopsy.
Results
Eight months of anti-inflammatory (topical steroids) and ocular surface-protective measures (autologous serum drops, bandage contact lenses, punctum plugs) yielded no improvement but rather resulted in partial stromal melting. In contrast, discontinuation of osimertinib led to a dramatic recovery within 1 week, after which the medication was continued at half the original dose. After 9 additional months, corneal defects recurred, but this time they were bilateral and took a full 2 and a half months to heal after osimertinib was stopped again. Similar variable clinical patterns have been reported in the literature for older first- and second-generation EGFR TKIs.
Conclusions
This case highlights the heterogeneous patterns of corneal adverse effects associated with EGFR TKIs, including variability in onset, laterality, and healing time after discontinuation. Ophthalmologists should maintain awareness of drug-induced toxicity in patients receiving these agents and consider early treatment suspension in collaboration with oncologists, regardless of the clinical presentation pattern.
Zitieren
APA
Kaufmann, C., Dressler, M., & Iselin, K. C. (2026). Heterogeneous Corneal Toxicity Among Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Focus on Osimertinib. Cornea Open, 5(3). https://doi.org/10.1097/coa.0000000000000087
Vancouver
Kaufmann C, Dressler M, Iselin KC. Heterogeneous Corneal Toxicity Among Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Focus on Osimertinib. Cornea Open. 2026;5(3). doi:10.1097/coa.0000000000000087
BibTeX
@article{Kaufmann2026,
author = {Kaufmann, Claude and Dressler, Marco and Iselin, Katja C.},
title = {Heterogeneous Corneal Toxicity Among Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Focus on Osimertinib},
journal = {Cornea Open},
year = {2026},
volume = {5},
number = {3},
doi = {10.1097/coa.0000000000000087}
}
EUVIMED